Wave Life Sciences (NASDAQ:WVE) announced its earnings results on Friday. The company reported ($1.28) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.26) by ($0.02), MarketWatch Earnings reports. Wave Life Sciences had a negative return on equity of 91.88% and a negative net margin of 1,473.26%. The company had revenue of $4.49 million for the quarter, compared to analyst estimates of $5.36 million.

NASDAQ WVE traded down $2.07 during trading hours on Friday, hitting $43.16. The company’s stock had a trading volume of 56,859 shares, compared to its average volume of 77,911. Wave Life Sciences has a twelve month low of $21.85 and a twelve month high of $56.00. The firm has a market capitalization of $1.33 billion, a P/E ratio of -11.21 and a beta of 1.10. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.11 and a quick ratio of 6.11.

A number of equities analysts have recently issued reports on the stock. BidaskClub upgraded shares of Wave Life Sciences from a “hold” rating to a “buy” rating in a research report on Tuesday. HC Wainwright reiterated a “buy” rating and set a $49.00 target price on shares of Wave Life Sciences in a research report on Monday, July 23rd. Stifel Nicolaus assumed coverage on shares of Wave Life Sciences in a research report on Monday, August 6th. They set a “buy” rating and a $56.00 target price on the stock. Finally, Mizuho set a $65.00 target price on shares of Wave Life Sciences and gave the stock a “buy” rating in a research report on Thursday, August 9th. One investment analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $58.40.

In related news, CFO Keith Regnante sold 29,500 shares of the stock in a transaction that occurred on Monday, September 24th. The shares were sold at an average price of $55.00, for a total value of $1,622,500.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Chris Francis sold 11,575 shares of the stock in a transaction that occurred on Tuesday, September 25th. The shares were sold at an average price of $56.00, for a total transaction of $648,200.00. The disclosure for this sale can be found here. Insiders sold 44,075 shares of company stock worth $2,435,700 over the last 90 days. 44.20% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION WARNING: “Wave Life Sciences (WVE) Releases Earnings Results, Misses Estimates By $0.02 EPS” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.thecerbatgem.com/2018/11/10/wave-life-sciences-wve-releases-earnings-results-misses-estimates-by-0-02-eps.html.

About Wave Life Sciences

Wave Life Sciences Ltd., a biotechnology company, designs, develops, and commercializes nucleic acid therapeutic candidates for genetically defined diseases by utilizing proprietary synthetic chemistry drug development platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Recommended Story: What is the Dividend Aristocrat Index?

Earnings History for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.